KROS today
$10.08+$0.54 (+5.66%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourBullish
1 hourExpanding
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $12.26
Key levels
Resistance$11.25
Resistance$10.63
Support$10.00
Support$8.98
Latest news & SEC filings
EarningsKeros Therapeutics Posts Q3 2026 Financials
ProductKeros Therapeutics sets 1H27 for first rinvatercept DMD trial results
SEC FilingKeros Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All KROS news →About Keros Therapeutics
Keros Therapeutics is a drug developer in the clinical testing phase, creating protein-based treatments for conditions tied to faulty signaling of the TGF-beta protein family. Its main candidate, rinvatercept, is aimed at muscle-wasting and nerve-related diseases including Duchenne muscular dystrophy and ALS, while elritercept targets insufficient red cells and platelets in certain bone marrow disorders. The company is based in the United States and has partnered with Takeda to develop and sell elritercept in most countries outside mainland China, Hong Kong, and Macau.
Based on the company's 10-K filed Mar 4, 2026.
Nasdaq · Healthcare
Keros Therapeutics, Inc. (KROS)
What Is the Price Target for KROS?
SEPT Low Target
$18.00
SEPT Mid Target
$18.00
SEPT High Target
$18.00
Analyst Consensus
$18.00
Is KROS a Buy or Sell Right Now?
Thesis
- •Revenue growing 161399.3% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for KROS.
Start Free Trial →Is KROS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$21.93
29
Moat Score
NONE
5/9
Piotroski Score
6.6
Altman Z-Score
What Is Smart Money Doing with KROS?
Insider Signal
SELLING
3 buys / 6 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Newton Charles W. | director | Sale | 550 | $6K | Jun 11, 2026 |
| Seth Alpna | director | Sale | 2,625 | $28K | Jun 4, 2026 |
| Knowles Julius | director | Sale | 2,625 | $28K | Jun 4, 2026 |
| Farzan Nima | director | Sale | 2,625 | $28K | Jun 4, 2026 |
| Knowles Julius | director | Buy | 7,142 | - | Jun 3, 2026 |
| Farzan Nima | director | Buy | 7,142 | - | Jun 3, 2026 |
| Seth Alpna | director | Buy | 7,142 | - | Jun 3, 2026 |
| GRAY MARY ANN | director | Buy | 7,142 | - | Jun 3, 2026 |
| BIENAIME JEAN JACQUES | director | Buy | 7,142 | - | Jun 3, 2026 |
| BIENAIME JEAN JACQUES | director | Buy | 1,000 | $11K | May 15, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →KROS Growth Story
Revenue YoY
161399.3%
3yr Revenue CAGR
N/A%
EPS Growth YoY
146%
FCF Growth YoY
165.1%
Revenue Trend
ACCELERATING
Dark Pool Trades for KROS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for KROS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:01:30 | $10.08 | 3,500 | $$35K | BUY |
| 17:56:13 | $10.26 | 1,400 | $$14K | SELL |
| 17:55:26 | $10.45 | 2,800 | $$29K | MIDPOINT |
| 17:55:26 | $10.45 | 1,100 | $$11K | SELL |
| 17:51:36 | $10.49 | 2,500 | $$26K | BUY |
5 dark pool trades shown · $$117K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Keros Therapeutics, Inc. (KROS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →KROS — frequently asked questions
What is KROS stock price today?
Keros Therapeutics, Inc. (KROS) is at $10.08, up 5.66% (+$0.54) at the Nov 12, 2026 close.
Why is KROS stock moving today?
Latest KROS news — Nov 6, 2026: Keros Therapeutics Posts Q3 2026 Financials · Nov 5, 2026: Keros Therapeutics sets 1H27 for first rinvatercept DMD trial results
What is the KROS price target?
The average analyst price target for KROS is $18.00, ranging from $18 to $18, based on 1 analysts. Latest: Wells Fargo maintains on Aug 4, 2026.
What do analysts rate KROS?
Analyst ratings for KROS: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did KROS beat earnings?
KROS last reported on Nov 4, 2026: EPS $0.70 vs -$0.96 expected — a beat of 172.9%.
Does KROS pay a dividend?
KROS does not currently pay a dividend.
What are KROS support and resistance levels?
Support: $10.00, $8.98. Resistance: $10.63, $11.25, $11.88.
What are insiders doing with KROS?
Insider activity: SELLING, 3 buys and 6 sells in the last 90 days.
What is the latest news on KROS?
Nov 6, 2026: Keros Therapeutics Posts Q3 2026 Financials · Nov 5, 2026: Keros Therapeutics sets 1H27 for first rinvatercept DMD trial results · Nov 5, 2026: Keros Therapeutics, Inc. filed a report on a major company event (Form 8-K)